Literature DB >> 20526747

Study of the interaction of the C-reactive protein monomer with the U937 monocyte.

Jing Zhao1, Xin-He Shi.   

Abstract

C-reactive protein (CRP) has two structurally distinct isoforms, the CRP pentamer and the CRP monomer. A role for the CRP monomer in atherosclerosis is emerging, but the underlying mechanisms are only beginning to be understood. Monocytes are an important contributor to atherosclerosis, and foam cell formation is the hallmark of atherogenesis. However, whether the CRP monomer can directly interact with the monocytes and modulate their responses remains unknown. Furthermore, although FcgammaRIII (CD16) has been identified as the receptor for the CRP monomer on neutrophils, its role in mediating the CRP monomer's biological effects in other cell types has been questioned. In this study, we investigated the interaction of the CRP monomer with the monocytes using the U937 monocytic cell line. The CRP monomer specifically binds to U937 cells. This binding is unique in that it is independent of FcgammaRs and insensitive to protease digestion of the cell surface proteins. Further assays revealed that the CRP monomer directly incorporates into the plasma membrane. Interestingly, the presence of the CRP monomer efficiently retards oxidized low-density lipoprotein-induced foam cell formation of PMA-differentiated U937 macrophages and peripheral blood monocytic cell-derived macrophages. These findings provide additional evidence for the notion that the CRP monomer is an active CRP isoform that plays a role in atherogenesis via the direct modulation of the behavior of the monocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20526747      PMCID: PMC6275878          DOI: 10.2478/s11658-010-0022-4

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  7 in total

1.  An Intrinsically Disordered Motif Mediates Diverse Actions of Monomeric C-reactive Protein.

Authors:  Hai-Yun Li; Jing Wang; Fan Meng; Zhe-Kun Jia; Yang Su; Qi-Feng Bai; Ling-Ling Lv; Fu-Rong Ma; Lawrence A Potempa; Yong-Bin Yan; Shang-Rong Ji; Yi Wu
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

2.  Presence of multimeric isoforms of human C-reactive protein in tissues and blood.

Authors:  Qiling Li; Wei Xu; Xue Xue; Qi Wang; Lu Han; Wenzhi Li; Shulan Lv; Dong Liu; Jendai Richards; Zhujun Shen; Li Ma; Qing Song
Journal:  Mol Med Rep       Date:  2016-11-03       Impact factor: 2.952

3.  Fucosyl-Agalactosyl IgG₁ Induces Cholangiocarcinoma Metastasis and Early Recurrence by Activating Tumor-Associated Macrophage.

Authors:  Ting-Tsung Chang; Hung-Wen Tsai; Cheng-Hsun Ho
Journal:  Cancers (Basel)       Date:  2018-11-21       Impact factor: 6.639

4.  Multimeric stability of human C-reactive protein in archived specimens.

Authors:  Qiling Li; Ting Kang; Xiaohua Tian; Yamin Ma; Min Li; Jendai Richards; Tameka Bythwood; Yueling Wang; Xu Li; Dong Liu; Li Ma; Qing Song
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

5.  The binding of monomeric C-reactive protein (mCRP) to Integrins αvβ3 and α4β1 is related to its pro-inflammatory action.

Authors:  Masaaki Fujita; Yoko K Takada; Yoshihiro Izumiya; Yoshikazu Takada
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

6.  Downregulation of miR-637 promotes vascular smooth muscle cell proliferation and migration via regulation of insulin-like growth factor-2.

Authors:  Ning Yang; Bo Dong; Yanqiu Song; Yang Li; Lu Kou; Jingyu Yang; Qin Qin
Journal:  Cell Mol Biol Lett       Date:  2020-05-07       Impact factor: 5.787

7.  Monomeric C-Reactive Protein in Serum With Markedly Elevated CRP Levels Shares Common Calcium-Dependent Ligand Binding Properties With an in vitro Dissociated Form of C-Reactive Protein.

Authors:  Robert D Williams; Jennifer A Moran; Anthony A Fryer; Jamie R Littlejohn; Harry M Williams; Trevor J Greenhough; Annette K Shrive
Journal:  Front Immunol       Date:  2020-02-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.